Establishment of a Rodent Glioblastoma Partial Resection Model for Chemotherapy by Local Drug Carriers—Sharing Experience
Authors:
- Carolin KubeltCKCarolin Kubelt
- Dana HellmoldDHDana Hellmold
- Eva PeschkeEPEva Peschke
- Margarethe HauckMHMargarethe Hauck
- Olga WillOWOlga Will
- Fabian SchüttFSFabian Schütt
- Ralph LuciusRLRalph Lucius
- Rainer AdelungRARainer Adelung
- Regina ScherließRSRegina Scherließ
- Jan-Bernd HövenerJHJan-Bernd Hövener
- Olav JansenOJOlav Jansen
- Michael SynowitzMSMichael Synowitz
Open Access
- 24 May 2023
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 11 (6) , 1518
Abstract
Local drug delivery systems (LDDS) represent a promising therapy strategy concerning the most common and malignant primary brain tumor glioblastoma (GBM). Nevertheless, to date, only a few systems have been clinically applied, and their success is very limited. Still, numerous new LDDS approaches are currently being developed. Here, (partial resection) GBM animal models play a key role, as such models are needed to evaluate the therapy prior to any human application. However, such models are complex to establish, and only a few reports detail the process. Here, we report our results of establishing a partial resection glioma model in rats suitable for evaluating LDDS. C6-bearing Wistar rats and U87MG-spheroids- and patient-derived glioma stem-like cells-bearing athymic rats underwent tumor resection followed by the implantation of an exemplary LDDS. Inoculation, tumor growth, residual tumor tissue, and GBM recurrence were reliably imaged using high-resolution Magnetic Resonance Imaging. The release from an exemplary LDDS was verified in vitro and in vivo using Fluorescence Molecular Tomography. The presented GBM partial resection model appears to be well suited to determine the efficiency of LDDS. By sharing our expertise, we intend to provide a powerful tool for the future testing of these very promising systems, paving their way into clinical application.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (GRK2154, 122-09-053)
- Kiel University and the Faculty of Medicine (GRK2154, 122-09-053)
- European Regional Development Fund (GRK2154, 122-09-053)
This publication has 45 references indexed in Scilit:
- In vivo models of primary brain tumors: pitfalls and perspectivesNeuro-Oncology, 2012
- Continuous local delivery of interferon-β stabilizes tumor vasculature in an orthotopic glioblastoma xenograft resection modelSurgery, 2011
- Effector T-Cell Infiltration Positively Impacts Survival of Glioblastoma Patients and Is Impaired by Tumor-Derived TGF-βClinical Cancer Research, 2011
- Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteriaOncogene, 2007
- Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progressionJournal of Neuro-Oncology, 2007
- Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell linesCancer Cell, 2006
- Gliadel® wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trialActa Neurochirurgica, 2006
- Risk Factors for Postcraniotomy Surgical Site Infection after 1,3‐Bis (2‐Chloroethyl)‐1‐Nitrosourea (Gliadel) Wafer PlacementClinical Infectious Diseases, 2003
- Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasionCell and tissue research, 2002
- Brain biocompatibility of a biodegradable, controlled‐release polymer in ratsJournal of Biomedical Materials Research, 1989